About: Modimelanotide

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, , Abbott Laboratories, AbbVie, and for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued.

thumbnail
Property Value
dbo:abstract
  • Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, , Abbott Laboratories, AbbVie, and for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued. (en)
dbo:casNumber
  • 926277-68-1
dbo:fdaUniiCode
  • 96C1EBE9CG
dbo:pubchem
  • 72941953
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 46801868 (xsd:integer)
dbo:wikiPageLength
  • 6275 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 993704801 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 113 (xsd:integer)
dbp:casNumber
  • 926277 (xsd:integer)
dbp:chemspiderid
  • 34988374 (xsd:integer)
dbp:h
  • 181 (xsd:integer)
dbp:iupacName
  • (N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide) (en)
dbp:n
  • 33 (xsd:integer)
dbp:o
  • 25 (xsd:integer)
dbp:pubchem
  • 72941953 (xsd:integer)
dbp:s
  • 1 (xsd:integer)
dbp:smiles
  • [H]/N=C/NCCC[C@@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NC[C@H]NCC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • WHRVKPBBRZHWTN-ZHHKRVSMSA-N (en)
dbp:synonyms
  • Acetylhexa-(L)-lysyl-α-MSH (en)
dbp:unii
  • 96 (xsd:integer)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, , Abbott Laboratories, AbbVie, and for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors. Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models, and development was not further pursued. (en)
rdfs:label
  • Modimelanotide (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License